Priveterra Acquisition Corp.
PMGM
NASDAQ Capital Market11.05
USD
-0.01
- -
CIK
0001837607
ISIN
US74275N1028
CUSIP
74275N102
Return %
Stock
S&P500
1Y
12.18
26.53
3Y
13.68
76.60
5Y
14.51
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Oleg Grodnensky
- Full Time Employees
- 5
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 300 SE 2nd Street Fort Lauderdale FL United States of America 33301
- IPO Date
- Apr 12, 2021
- CIK
- 0001837607
- Website
- tastemakeracquisition.com
- Similar Companies
- Business
- Priveterra Acquisition Corp. Priveterra Acquisition Corp. II (Nasdaq: PMGM) serves as a blank check company, or special purpose acquisition company (SPAC), formed to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, with a primary focus on the life sciences sector. The company offers no current products or services beyond its SPAC structure, which involves raising capital through an initial public offering of units comprising Class A ordinary shares and warrants, holding proceeds in trust for deployment into a target acquisition, and pursuing strategic transactions to take private companies public. Priveterra Acquisition Corp. II operates from headquarters in Fort Lauderdale, Florida, where it was incorporated in 2020 under the sponsorship of Robert Palmisano, Priveterra Capital, LLC, and key executives including President Vikram Malik and COO/CFO Oleg Grodnensky; it targets life sciences enterprises at various development stages across North America, with potential for global opportunities post-combination. In July 2023, the original Priveterra Acquisition Corp. (distinct but predecessor entity) completed its business combination with AEON Biopharma, Inc., a Phase 3-stage biopharmaceutical company developing proprietary neurotoxins for migraine prevention and other conditions, resulting in the combined entity relisting on NYSE American under AEON and AEON WS tickers, with Palmisano joining as a board director. More recently, Priveterra Acquisition Corp. II, formerly known as Tastemaker Acquisition Corp., terminated a proposed business combination with Quality Gold, Inc. in June 2023 due to challenging market conditions and has faced Nasdaq compliance issues, including a 2024 notice for late 10-K filing and prior market value deficiencies below $35 million, while continuing to seek a suitable target amid high redemptions that reduced its trust from $276 million. The company maintains no active subsidiaries or parent relationships and focuses on disciplined due diligence for value creation through capital markets transactions in corporate finance and mergers.
Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.
Priveterra Acquisition Corp. Announces Authorization to List on NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.
Priveterra Acquisition says it will list on NYSE after AEON combination
Priveterra Acquisition Corp. Announces Intention to Transfer to NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.